About molinger

This author has not yet filled in any details.
So far molinger has created 3 blog entries.

Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial

Study Meets Primary Endpoint of Slowing of ALS as Measured by the ALSFRS-R December 17, 2019 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M. Healey & AMG Center for ALS at Mass [...]

Amylyx Announces Appointment of Debra Canner as Global Head of Human Resources

Passionate HR Leader Brings 20+ Years of Experience to Solidify the Growth of the Company’s Team December 12, 2019 09:30 AM Eastern Standard Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., today announced the appointment of Debra Canner as the company’s first Global Head of Human Resources. Deb will serve on Amylyx’ Executive Team, overseeing the [...]

Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS

October 04, 2019 12:50 PM Eastern Daylight Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the last participant has completed the planned 24 weeks of study treatment in CENTAUR, a clinical trial assessing the safety and [...]